Serotype-independent Pneumococcal Experimental Vaccines That Induce Cellular As Well As Humoral Immunity

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2012 Feb 7

PMID 22308483

Citations 44

Authors

Richard Malley

Porter W Anderson

Affiliations

Soon will be listed here.

Abstract

For prevention of Streptococcus pneumoniae (pneumococcus) infections in infancy, protein-conjugated capsular polysaccharide vaccines provide serotype-specific, antibody-mediated immunity but do not cover all of the 90+ capsule serotypes. Therefore, microbiologists have sought protective noncapsular antigens common to all strains. Alternatively, we investigated killed cells of a noncapsulated strain, which expose many such common antigens. Given to mice intranasally, this vaccine elicits antibody-independent, CD4+ T lymphocyte-dependent accelerated clearance of pneumococci of various serotypes from the nasopharynx mediated by the cytokine IL-17A. Such immunity may reproduce the natural resistance that develops in infants before capsular antibodies arise. Given by injection, the killed cell vaccine induces bifunctional immunity: plasma antibodies protective against fatal pneumonia challenge, as well as IL-17A-mediated nasopharyngeal clearance. Human testing of this inexpensive candidate vaccine by intramuscular injection is planned. Bacterial cellular vaccines are complex--a challenge for reproducibility. However, when several known protective antigens were deleted, the killed pneumococcal vaccine was still protective. This antigenic redundancy may prevent vaccine escape variants by recombinational loss, which is frequent in pneumococcus. Biochemically defined immunogens with bifunctional activity have also been devised. These immunogens are three-component conjugates in which cell wall teichoic acid (a common antigen capable of T cell activation) is coupled to a genetic fusion of two common pneumococcal proteins: a protective surface antigen and a derivative of pneumolysin, which provides TLR4 agonist activity and induces antitoxic immunity. Such constructs induce accelerated clearance when given intranasally and induce both immune mechanisms when injected. The defined composition permits analysis of structure-function activity.

Citing Articles

Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections.

Cardoso K, de Souza L, da Silva Santos B, de Carvalho K, da Silva Messias S, de Faria Goncalves A NPJ Vaccines. 2024; 9(1):246.

PMID: 39702744 PMC: 11659394. DOI: 10.1038/s41541-024-01033-5.

Microbiota and Immunity during Respiratory Infections: Lung and Gut Affair.

Marrella V, Nicchiotti F, Cassani B Int J Mol Sci. 2024; 25(7).

PMID: 38612860 PMC: 11012346. DOI: 10.3390/ijms25074051.

GL7 ligand expression defines a novel subset of CD4 T cells in lungs recovered from pneumococcus.

De Ana C, Shenoy A, Barker K, Arafa E, Etesami N, Korkmaz F Mucosal Immunol. 2023; 16(5):699-710.

PMID: 37604254 PMC: 10591822. DOI: 10.1016/j.mucimm.2023.07.004.

Antigen-specific memory Th17 cells promote cross-protection against nontypeable Haemophilus influenzae after mild influenza A virus infection.

Zhang X, Yang Y, Chen S, Li W, Li Y, Akerley B Mucosal Immunol. 2023; 16(2):153-166.

PMID: 36736665 PMC: 10343962. DOI: 10.1016/j.mucimm.2023.01.007.

Targeted Transcriptomic Screen of Pneumococcal Genes Expressed during Murine and Human Infection.

Basset A, Wall E, Mitsi E, Deshusses C, Daly R, Pojar S Infect Immun. 2022; 90(7):e0017522.

PMID: 35674445 PMC: 9302103. DOI: 10.1128/iai.00175-22.

References

Malley R, Srivastava A, Lipsitch M, Thompson C, Watkins C, Tzianabos A . Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun. 2006; 74(4):2187-95. PMC: 1418935. DOI: 10.1128/IAI.74.4.2187-2195.2006. View

McCool T, Weiser J . Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect Immun. 2004; 72(10):5807-13. PMC: 517579. DOI: 10.1128/IAI.72.10.5807-5813.2004. View

Xin W, Li Y, Mo H, Roland K, Curtiss 3rd R . PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun. 2009; 77(10):4518-28. PMC: 2747926. DOI: 10.1128/IAI.00486-09. View

Moffitt K, Gierahn T, Lu Y, Gouveia P, Alderson M, Flechtner J . T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe. 2011; 9(2):158-65. PMC: 3061323. DOI: 10.1016/j.chom.2011.01.007. View

Briles D, Yother J, McDaniel L . Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis. 1988; 10 Suppl 2:S372-4. DOI: 10.1093/cid/10.supplement_2.s372. View

Blander J, Medzhitov R . Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006; 440(7085):808-12. DOI: 10.1038/nature04596. View

AVERY O, GOEBEL W . CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS. J Exp Med. 2009; 50(4):533-50. PMC: 2131643. DOI: 10.1084/jem.50.4.533. View

Weiser J, Austrian R, Sreenivasan P, Masure H . Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun. 1994; 62(6):2582-9. PMC: 186548. DOI: 10.1128/iai.62.6.2582-2589.1994. View

Tomasz A . Surface components of Streptococcus pneumoniae. Rev Infect Dis. 1981; 3(2):190-211. DOI: 10.1093/clinids/3.2.190. View

10.

Chien Y, Klugman K, Morens D . Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis. 2010; 202(11):1639-48. PMC: 3107550. DOI: 10.1086/657144. View

11.

Weinberger D, Malley R, Lipsitch M . Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011; 378(9807):1962-73. PMC: 3256741. DOI: 10.1016/S0140-6736(10)62225-8. View

12.

Weiser J . The pneumococcus: why a commensal misbehaves. J Mol Med (Berl). 2009; 88(2):97-102. PMC: 4487619. DOI: 10.1007/s00109-009-0557-x. View

13.

Lipsitch M, Whitney C, Zell E, Kaijalainen T, Dagan R, Malley R . Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?. PLoS Med. 2005; 2(1):e15. PMC: 545206. DOI: 10.1371/journal.pmed.0020015. View

14.

Brereton C, Sutton C, Ross P, Iwakura Y, Pizza M, Rappuoli R . Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol. 2011; 186(10):5896-906. DOI: 10.4049/jimmunol.1003789. View

15.

Ye P, Garvey P, Zhang P, Nelson S, Bagby G, Summer W . Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001; 25(3):335-40. DOI: 10.1165/ajrcmb.25.3.4424. View

16.

Macleod C, HODGES R, Heidelberger M, BERNHARD W . PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES. J Exp Med. 2009; 82(6):445-65. PMC: 2135567. View

17.

Haneberg B, Herland Berstad A, Holst J . Bacteria-derived particles as adjuvants for non-replicating nasal vaccines. Adv Drug Deliv Rev. 2001; 51(1-3):143-7. DOI: 10.1016/s0169-409x(01)00163-6. View

18.

Ogunniyi A, Folland R, Briles D, Hollingshead S, Paton J . Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun. 2000; 68(5):3028-33. PMC: 97524. DOI: 10.1128/IAI.68.5.3028-3033.2000. View

19.

Paton J, Lock R, Hansman D . Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun. 1983; 40(2):548-52. PMC: 264890. DOI: 10.1128/iai.40.2.548-552.1983. View

20.

Briles D, Ades E, Paton J, Sampson J, Carlone G, Huebner R . Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun. 2000; 68(2):796-800. PMC: 97207. DOI: 10.1128/IAI.68.2.796-800.2000. View